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Abstract
Background. Non-dipping hypertension might be associated with increased cardiovascular risk and multiple 
diseases. The aim of our study was to assess if there are parameters identified in 24-hour ECG-Holter monitoring 
(ECG-Holter), transthoracic echocardiography (TTE), ECG parameters or laboratory data that allow prediction of 
circadian blood pressure profile (CBPP). 
Material and methods. One hundred and three consecutive patients (male: 50.5%), who underwent 24-hour ambu-
latory BP measurement and ECG-Holter simultaneously were analyzed. We divided patients into 3 groups: dipping 
was defined as 10–20% (28.2%), non-dipping as < 10% (50.5%) fall in nocturnal BP and reverse-dipping as higher 
nocturnal than diurnal BP (21.4%). Additionally, we performed TTE and laboratory check-up in all patients. We 
built multivariable models for nocturnal fall in systolic BP (SBP) and CBPP.
Results. Multivariable model based on clinical factors was: nocturnal fall in SBP (%) = [13.28 – 0.11 × age – 8.33 × (di-
lated cardiomyopathy) – 5.95 × PAD – 6.02 × a-adrenolytic]. Multivariable model based on laboratory, echocar-
diographic and electrocardiographic parameters was: nocturnal fall in SBP (%) = [–27.28 + 1.47 × hemoglo- 
bin – 0.14 × CK-MB + 0.14 × maximal heart rate]. Multivariable model for CBPP based on clinical factors included 
use of b- or a-adrenolytics or torasemide.
Conclusions. We proved that nocturnal fall in SBP and CBPP could be predicted based on ECG-Holter parameters, 
laboratory data and TTE results, as well as based on detailed medical history. These findings may have implications 
on care of patients with hypertension.
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Introduction
Hypertension is a growing problem, and current-
ly, there are over 1 billion hypertensive individuals 
worldwide [1, 2]. Some diseases, such as autonomic 
neuropathies, obstructive sleep apnea, diabetes, au-
tonomic dysfunction, and chronic kidney disease 
(CKD), also seem to relate to lower fall in nocturnal 
blood pressure (BP) [3, 4]. Patients affected with sec-
ondary or malignant hypertension also have higher 
prevalence of non-dipping pattern of circadian blood 
pressure profile (CBPP) [3, 4]. 
Recently published study suggests that asleep 
blood pressure is the most important risk factor for 
cardiovascular events which can be derived from BP 
values. In the study of Hermida et al., the asleep sys-
tolic BP was the most important risk factor for the 
primary outcome (defined as composite of cardiovas-
cular death, myocardial infarction, coronary revascu-
larization, heart failure and stroke) during 5.1-year 
median follow-up, and it was regardless of office and 
awake systolic BP values. The authors emphasize 
also the fact that attenuation of above-mentioned 
parameter was the most significant marker of event-
free survival [5].
Despite all above-mentioned facts the availability 
of 24-hour ambulatory blood pressure monitoring 
(ABPM) is rather low. The awareness about these 
novel goals in hypertension treatment is also small. 
Furthermore, little is known about factors either 
determining or allowing predicting CBPP, besides 
above-mentioned comorbidities. The aim of the 
study was to clarify whether there are such factors 
among 24-hour ECG Holter monitoring (ECG- 
-Holter), transthoracic echocardiography (TTE), 
ECG parameters or laboratory data. 
Material and methods
Study population
This was a retrospective study analyzing data of 103 
patients hospitalized in the Department of Cardiolo-
gy and Hypertension in Central Research Hospital of 
the Ministry of Interior in Warsaw between January 
2012 and December 2013. Consecutive hypertensive 
patients, who simultaneously underwent ABPM and 
ECG-Holter, were included into analysis. According 
to nocturnal BP fall pattern we divided the patients 
into three groups: dippers, non-dippers, reverse-
dippers. Dipping was defined as a 10–20% fall in 
nocturnal systolic BP (SBP), non-dipping as less than 
10%, and reverse-dipping as 0% at most fall in noc-
turnal SBP [6, 7]. Collected data were analyzed retro-
spectively and Local Ethics Committee gave consent 
to conduct the study. All procedures were performed 
in accordance with the Declaration of Helsinki on 
the treatment of human subjects. 
Measurements
We used Tracker NIBP2 SpaceLabs Healthcare and 
ABP 90217-7Q SpaceLabs Healthcare devices to ob-
tain ABPM and Lifecard CF Reynolds Medical de-
vice to assess ECG-Holter. Measurements of BP were 
performed every 10 minutes during awake hours and 
every 30 minutes during the night-time. Addition-
ally, all patients underwent TTE with Philips iE-33 
and EPIQ ultrasound machines.
Statistical analysis
Statistical analysis was performed with R version 
3.1.2 [8]. Continuous variables are presented as 
number of observations and mean with standard de-
viation, categorical variables are reported as frequen-
cies and percentages. The distribution of continuous 
variables was first analyzed with Shapiro-Wilk test of 
normality and then, according to the results, ANO-
VA test or Kruskal-Wallis test were used. Categorical 
variables were compared using Fisher’s exact test. 
The significance level was set at 0.05. The impact of 
clinical, laboratory, echocardiographic and electro-
cardiographic factors on nocturnal fall in SBP and 
CBPP was analyzed with linear regression analysis 
and ordinal logistic regression analysis, respectively. 
Univariable and mutlivariable analyses were per-
formed. Two multivariable models were built, with 
independent variables chosen from clinical factors 
and from laboratory, echocardiographic and electro-
cardiographic parameters for each dependent vari-
able (nocturnal fall in SBP and CBPP). Variables 
considered in multivariable models were chosen from 
the set of variables with Wald’s test p-value less than 
0.25 in univariable analysis and that were classified 
in expert analysis as having potential influence on 
dependent variables. Multivariable models were se-
lected with backward elimination procedure. Linear 
regression coefficients or proportional odds ratios 
were reported, with 95% confidence interval and 
Wald’s test p-values, respectively. 
Results
One hundred three consecutive patients (male: 
50.5%) with mean age 63.9 (± 17.7) years who 
simultaneously underwent ABPM and ECG-Holt-
er were included in further analysis. According to 
ABPM outcomes 29 (28%) patients were classified as 
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dippers, 52 (50%) as non-dippers and consecutive 22 
(21%) as reverse-dippers. The reverse-dipper group 
was the oldest, with mean age 74.9 ± 10.9 years (p < 
0.001). Study population characteristics are present-
ed in Table I. There were significant differences be-
tween groups in occurrence of CKD and peripheral 
artery disease (PAD), with higher prevalence of those 
diseases in non-dipper and the highest in reverse-
dipper group. In Table I we also included compari-
son of drugs taken by patients’ subgroups. We found 
that reverse-dippers were most likely to take both: 
b- and a-adrenolytics as well as torasemide. Table I 
also includes mean values of diurnal and nightly, 
both systolic and diastolic, BP. In Table II we present 
laboratory as well as TTE and in Table  III ECG- 
-Holter parameters.
The multivariable model for nocturnal fall in SBP 
based on clinical factors was:
Nocturnal fall in SBP [%] = 13.28 – 0.11 × age  
– 8.33 × DCM – 5.95 × PAD  
– 6.02 × a-adrenolytic
According to the presented model, if a patient’s 
age increases by 1 year, nocturnal fall in SBP decreas-
es by 0.11% [95% confidence interval (CI): –0.187 
to –0.029], if a patient has dilated cardiomyopathy 
(DCM), PAD or uses a-adrenolytics, nocturnal fall 
in SBP decreases by 8.33% (95% CI: –15.836 to 
–0.823), 5.95% (95% CI: –10.540 to –1.361) and 
6.02% (95% CI: –10.010 to –2.024), respectively 
(Tab. IV).
Table I. Population characteristics
Dipper 
(29 pts)
Non-dipper 
(52 pts)
Reverse-dipper
(22 pts)
Age (years) 55.24 ± 17.83 63.98 ± 17.46 74.91 ± 10.86 p < 0.001
Gender (M/F) 16/13 30/22 6/16 p = 0.05
SBP day [mm Hg] 129.72 ± 11.30 127.48 ± 13.81 125.77 ± 15.32 p = 0.58
SBP night [mm Hg] 111.55 ± 9.16 121.58 ± 13.73 133.00 ± 18.04 p < 0.001
SBP fall 13.93 ± 2.83 4.63 ± 2.91 -5.61 ± 3.71 p < 0.001
DBP day [mm Hg] 74.41 ± 8.19 71.23 ± 8.67 67.45 ± 6.53 p = 0.009
DBP night [mm Hg] 61.34 ± 6.67 65.29 ± 7.87 67.86 ± 8.05 p = 0.009
DBP fall 17.46 ± 3.93 8.21 ± 5.32 -0.53 ± 5.35 p < 0.001
HF 8 (27.59%) 17 (32.69%) 11 (52.38%) p = 0.19
HF-REF 0 (0.00%) 1 (1.92%) 0 (0.00%) p > 0.999
HF-PEF 6 (20.69%) 15 (28.85%) 10 (47.62%) p = 0.13
CKD 1 (3.70%) 9 (17.65%) 6 (30.00%) p = 0.05
PAD 1 (4.00%) 3 (5.88%) 5 (26.32%) p = 0.03
DCM 0 (0.00%) 2 (3.85%) 2 (10.00%) p = 0.18
OSA 7 (25.00%) 13 (25.00%) 2 (9.09%) p = 0.3
DM 4 (14.29%) 7 (13.73%) 2 (10.00%) p > 0.999
AF 3 (10.34%) 15 (29.41%) 8 (36.36%) p = 0.06
b-adrenolytics 15 (57.69%) 32 (69.57%) 19 (95.00%) p = 0.01
a-adrenolytics 0 (0.00%) 6 (13.04%) 6 (30.00%) p = 0.009
Ca-antagonists 9 (34.62%) 26 (56.52%) 9 (45.00%) p = 0.2
ACE-I 16 (61.54%) 22 (47.83%) 13 (65.00%) p = 0.39
ARB 3 (11.54%) 14 (30.43%) 6 (30.00%) p = 0.16
Aldosterone antagonists 0 (0.00%) 7 (15.22%) 1 (5.00%) p = 0.07
Furosemide 0 (0.00%) 8 (17.39%) 2 (10.00%) p = 0.06
Torasemide 1 (3.85%) 2 (4.35%) 7 (35.00%) p = 0.002
pts — patients; p — overall p-value for 3-group comparison of means (ANOVA test) or distributions (Kruskal-Wallis test) for continuous variables and percentages (c2 test) for categorical variables; SBP — systolic blood 
pressure; DBP — diastolic blood pressure; HF — heart failure; HF-REF — HF with restricted ejection fraction; HF-PEF — HF with preserved ejection fraction; CKD — chronic kidney disease; PAD — peripheral artery 
disease; DCM — dilated cardiomyopathy; OSA – obstructive sleep apnea syndrome; DM — diabetes mellitus; AF — atrial fibrillation; ACE-I — angiotensin-converting-enzyme inhibitor; ARB — angiotensin II receptor 
blocker
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The multivariable model for nocturnal fall in SBP 
based on laboratory, TTE and ECG parameters was:
Nocturnal fall of SBP [%] = –27.28 + 1.47 × HGB  
– 0.14 × CK – MB + 0.14 × HRmax
According to the presented model, if a patient’s he-
moglobin concentration (HGB), creatinine kinase MB 
isoenzyme (CK-MB) or maximal heart rate (HRmax) 
increases by 1 unit, nocturnal fall in SBP increases by 
1.47% [95% CI: 0.447 to 2.487), decreases by 0.14% 
(95% CI: –0.271 to –0.002) or increases by 0.14% 
(95% CI: 0.051 to 0.223), respectively (Tab. V).
The multivariable model for CBPP based on clini-
cal factors is presented in Table VI. According to 
that model, if patient uses: b- or a-adrenolytics or 
Table II. Laboratory and echocardiographic findings
Dipper 
(29 pts)
Non-dipper 
(52 pts)
Reverse-dipper
(22 pts)
HGB [g/dL] 14.30 ± 1.42 13.84 ± 1.57 12.70 ± 1.40 p = 0.002
RBC [× 106/µL] 4.81 ± 0.56 4.61 ± 0.51 4.28 ± 0.46 p = 0.003
HCT (%) 42.24 ± 3.82 41.57 ± 4.15 39.04 ± 3.13 p = 0.02
PLT [× 109/L] 207.75 ± 46.43 199.96 ± 58.39 212.40 ± 62.87 p = 0.68
MCV [fL] 88.21 ± 3.73 89.97 ± 4.70 91.84 ± 6.20 p = 0.09
MCH [pg] 29.76 ± 1.17 29.99 ± 1.73 30.02 ± 1.97 p = 0.81
MCHC [g/dL] 33.66 ± 1.16 33.36 ± 0.96 32.73 ± 0.97 p = 0.001
Urea [mg/dL] 30.21 ± 5.85 41.04 ± 32.72 46.71 ± 21.11 p = 0.03
eGFR [mL/min/1.73 m2] 88.15 ± 18.77 80.35 ± 26.42 76.35 ± 29.04 p = 0.25
Creatinine [mg/dL] 0.84 ± 0.17 1.15 ± 1.70 0.93 ± 0.44 p = 0.47
AST [U/L] 20.86 ± 5.89 26.02 ± 14.03 29.88 ± 30.01 p = 0.4
ALT [U/L] 25.30 ± 13.02 31.49 ± 30.46 23.59 ± 30.22 p = 0.02
NT-proBNP [pg/mL] 332.40 ± 359.33 1490.38 ± 2507.92 1414.30 ± 2919.21 p = 0.65
CK [µg/L] 109.56 ± 38.57 92.66 ± 49.09 119.62 ± 65.23 p = 0.1
CK-MB [µg/L] 16.56 ± 5.09 18.75 ± 9.88 24.82 ± 16.82 p = 0.03
EF (%) 62.39 ± 4.69 61.35 ± 7.23 59.86 ± 6.23 p = 0.13
LVDd [mm] 50.31 ± 4.43 50.18 ± 5.88 50.10 ± 5.94 p = 0.7
RVDd [mm] 31.50 ± 4.53 32.73 ± 4.86 31.45 ± 6.11 p = 0.48
LAD [mm] 40.21 ± 4.80 43.75 ± 6.15 41.76 ± 5.22 p = 0.03
IVSd [mm] 10.59 ± 1.21 10.94 ± 1.77 10.11 ± 3.00 p = 0.68
PWDd [mm] 10.34 ± 1.34 10.76 ± 1.73 10.14 ± 1.53 p = 0.26
TAPSE [mm] 22.00 ± 4.24 23.00 ± 5.89 21.83 ± 2.99 p = 0.9
IVC [mm] 16.00 ± 4.58 20.50 ± 5.45 15.46 ± 7.98 p = 0.66
VHD
  AR 7 (25.00%) 18 (35.29%) 6 (28.57%) p = 0.63
  AS 0 (0.00%) 2 (3.92%) 0 (0.00%) p = 0.71
  MR 20 (68.97%) 36 (70.59%) 18 (85.71%) p = 0.37
  MS 0 (0.00%) 0 (0.00%) 0 (0.00%) NA
  TR 10 (35.71%) 28 (54.90%) 12 (57.14%) p = 0.24
  TS 0 (0%) 2 (3.92%) 0 (0.00%) p = 0.71
  PR 0 (0.00%) 1 (1.96%) 1 (4.76%) p = 0.45
  PS 0 (0.00%) 0 (0.00%) 0 (0.00%) NA
pts — patients; p — overall p-value for 3-group comparison of means (ANOVA test) or distributions (Kruskal-Wallis test) for continuous variables; HGB — hemoglobin; RBC — red blood cells count; HCT — hematocrit; 
PLT — platelets count; MCV — mean corpuscular volume; MCH — mean corpuscular hemoglobin; MCHC — mean corpuscular hemoglobin concentration; eGFR — estimated glomerular filtration rate; 
CRP — C-reactive protein; AST — aspartate transaminase; ALT — alanine transaminase; NT-proBNP — N-terminal of the prohormone brain natriuretic peptide; CK — creatinine kinase; CK-MB — CK MB isoenzyme; 
EF — ejection fraction, LVDd — left ventricle end diastolic dimension; RVDd — right ventricle end diastolic dimension; LAD — left atrium diameter; IVSd — intraventricular septum end-diastolic diameter;  
PWDd — posterior wall end-diastolic diameter; TAPSE — tricuspid annular plane systolic excursion; IVC — inferior vena cava; VHD — valvular heart disease; AR — aortic regurgitation; AS — aortic stenosis;  
MR — mitral regurgitation; MS — mitral stenosis; TR — tricuspid regurgitation; TS — tricuspid stenosis; PR — pulmonary regurgitation; PS — pulmonary stenosis
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torasemide, odds ratios of being in non-dipper or 
reverse dipper group versus dipper group or being in 
reverse dipper group versus dipper and non-dipper 
group were 3.26 (95% CI: 1.337 to 8.280), 5.80 
(95% CI: 1.678 to 22.110) and 8.69 (95% CI: 
1.976 to 48.034), respectively. 
Table III. 24-hour ECG Holter parameters
Dipper (29 pts) Non-dipper (52 pts) Reverse-dipper (22 pts)
Number of beats 77498.38 ± 16268.83 75538.67 ± 18449.94 82990.00 ± 24477.60 p = 0.89
HRmean 66.66 ± 7.33 68.08 ± 15.63 65.14 ± 6.34 p = 0.8
HRmax 109.45 ± 17.21 102.50 ± 18.43 95.77 ± 12.91 p = 0.02
HRmin 51.31 ± 6.87 52.56 ± 6.78 52.86 ± 6.06 p = 0.65
AF 7.08 ± 38.11 7.84 ± 27.14 9.09 ± 29.42 p = 0.71
Pause 0.24 ± 0.83 2.35 ± 11.32 1.36 ± 4.01 p = 0.78
Pause max (s) 0.24 ± 0.74 0.43 ± 1.11 0.30 ± 0.78 p = 0.78
Bradycardias 0.14 ± 0.74 1.38 ± 4.60 0.14 ± 0.64 p = 0.13
VT 0.03 ± 0.19 0.31 ± 1.55 0.05 ± 0.21 p = 0.5
ExV 482.48 ± 2274.48 426.31 ± 1263.96 259.68 ± 722.38 p = 0.07
ExV/h 70.03 ± 258.05 54.58 ± 132.47 41.18 ± 101.26 p = 0.05
ExV/min 3.31 ± 8.70 5.19 ± 8.47 4.91 ± 5.13 p = 0.03
Couples 1.66 ± 8.91 0.92 ± 3.09 14.82 ± 67.05 p = 0.02
Triplets 0.03 ± 0.19 0.06 ± 0.31 0.05 ± 0.21 p = 0.98
Bigeminy 16.76 ± 79.00 7.31 ± 26.85 0.82 ± 2.44 p = 0.78
ExSV 120.97 ± 426.45 180.27 ± 408.43 1158.27 ± 2947.52 p = 0.05
SVT 1.52 ± 4.36 3.25 ± 14.29 39.64 ± 176.11 p = 0.03
ExSV/h 27.17 ± 104.68 27.40 ± 63.17 142.86 ± 321.07 p = 0.07
ExSV/min 4.59 ± 7.11 5.40 ± 8.14 10.50 ± 13.91 p = 0.05
Couples 1.64 ± 3.84 5.90 ± 20.13 82.77 ± 335.52 p = 0.02
P [ms] 84.86 ± 22.58 80.55 ± 32.14 65.91 ± 39.36 p = 0.29
PQ [ms] 145.17 ± 43.88 149.71 ± 56.68 142.73 ± 80.84 p = 0.75
QRS [ms] 98.28 ± 26.02 120.10 ± 101.88 102.86 ± 23.45 p = 0.5
ST [ms] 138.21 ± 137.70 154.90 ± 143.47 154.55 ± 51.34 p = 0.04
ECG HR 73.62 ± 13.04 69.60 ± 15.28 64.73 ± 16.44 p = 0.05
QTc [ms] 445.89 ± 73.36 428.76 ± 60.99 436.19 ±  39.26 p = 0.66
pts — patients; p — overall p-value for 3-group comparison of means (ANOVA test) or distributions (Kruskal-Wallis test) for continuous variables; HR — heart rate; AF — atrial fibrillation; VT — ventricular tachycardia; 
exV — ventricular extrasystoles; exV/h — exV per hour; exV/min — exVper minute; exSV — supraventricular extrasystoles; SVT — supraventricular tachycardia; exSV/h — exSV per hour; exSV/min — exSV per 
minute; QTc — corrected QT
Table IV. Multivariable model for nocturnal fall in systolic blood 
pressure (SBP) based on clinical factors
Linear regression coefficient  
(95% CI)
Age –0.108 (–0.187 to –0.029) p = 0.008
DCM –8.329 (–15.836 to –0.823) p = 0.03
PAD –5.951 (–10.540 to –1.361) p = 0.01
a-adrenolytics –6.017 (–10.010 to –2.024) p = 0.004
Variables included in multivariable model for nocturnal fall in SBP based on clinical factors. CI — confi-
dence interval; DCM — dilated cardiomyopathy; PAD — peripheral artery disease
Table V. Multivariable model for nocturnal fall in systolic blood 
pressure (SBP) based on laboratory, transthoracic echocardio-
graphy (TTE) and electrocardiography (ECG) parameters
Linear regression coefficient  
(95% CI)
HGB 1.467 (0.447 to 2.487) p = 0.006
CK-MB –0.136 (–0.271 to –0.002) p = 0.05
HRmax 0.137 (0.051 to 0.223) p = 0.002
Variables included in multivariable model for nocturnal fall in SBP based on all other assessed factors. 
CI — confidence interval; HGB — hemoglobin; CK-MB — CK MB isoenzyme; HR — heart rate
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Discussion
Millar-Craig et al. described circadian variation of 
BP in 1978 [9]. They used continuous intra-arte-
rial monitoring. Nowadays ABPM is a noninvasive 
method to obtain CBPP [10]. Others proved that 
non-dipping pattern in hypertensive individuals 
might be associated with increased cardiovascular 
risk [6]. The lower or lack of fall in nocturnal BP 
could also cause target organ damage. Literature 
brings evidence that non-dipping blood pressure 
profile relates to left ventricle hypertrophy, cardiac 
functional alternations, renal damage, carotid artery 
abnormalities and cerebrovascular diseases [11–14].
Our study demonstrated that CBPP could be pre-
dicted according to clinical factors as well as laboratory, 
TTE and ECG parameters. The multivariable model 
for nocturnal fall in SBP based on clinical factors in-
cluded age, diagnosis of DCM or PAD and the use of 
a-adrenolytics. Others described lower sleep-time de-
cline in SBP in older patients and it is known that older 
patients are more likely to be non-dippers or reverse 
dippers [15, 16]. Some authors report that dipping 
status in hypertension influences cardiac structure and 
function [13, 17, 18]. Although, other studies failed 
to show statistically significant differences in cardiac 
structural or functional alternations between dippers 
and non-dippers [19]. We did not find any associa-
tions between CBPP and DCM. Wyss et al. showed 
hypertension as cardiovascular risk factor, though not 
associated with severity of PAD in multivariate models 
[20]. However, Vasunta et al. proved that non-dipping 
status in hypertension was a risk factor for early ath-
erosclerosis development (intima-media thickness as-
sessment) [21]. In other studies, association between 
non-dipping pattern of hypertension and early stages 
of atherosclerosis was also proven and influence of 
study population age was also emphasized [22]. The 
fact that the patients who took a-adrenolytics were 
more likely to have lower fall in nocturnal BP could 
be explained by the fact that this class of drugs reduces 
nightly BP and restores dipping CBPP in non-dippers 
[23]. On the other hand, Pickering et al. showed that 
doxazosin lowered mostly morning BP and had rela-
tively little influence on nightly BP [24]. According to 
Table VI. Multivariable model for circadian blood pressure pattern 
(CBPP) based on clinical factors
Proportional OR (95% CI) 
b-adrenolytics 3.264 (1.337 to 8.280) p = 0.01
a-adrenolytics 5.799 (1.678 to 22.110) p = 0.007
Torasemide 8.686 (1.976 to 48.034) p = 0.007
Variables included in multivariable model for CBPP based on clinical factors. OR — odds ratio;  
CI — confidence interval
the current guidelines of arterial hypertension manage-
ment, b-blockers are recommended as antihypertensive 
drugs [25]. However, no studies comparing bedtime 
and morning administration of b-blockers have been 
conducted so far. These drugs are well known to influ-
ence daily BP, with minor influence on nightly BP 
[26]. There are only a few studies assessing influence of 
diuretics on dipping pattern. Uzu and Kimura showed 
that despite the fact that hydrochlorothiazide did not 
change CBPP in dippers, it changed non-dipping into 
dipping pattern in salt-sensitive hypertensive patients 
[27]. We did not find any associations between to-
rasemide administration and CBPP. Furthermore, 
there is still little data comparing furosemide versus 
torasemide or other loop diuretics in the treatment 
of hypertension as well as there is little evidence upon 
which to base dosing of loop diuretics in the treatment 
of hypertension. We found no data analyzing different 
loop diuretics or different groups of diuretics in the 
context of hypertension dipping status [28].
Among laboratory, TTE and ECG parameters, 
HGB, CK-MB and HRmax seemed to have influence 
on nocturnal fall in SBP. We could not find any asso-
ciations between HGB parameters and CBPP. Though 
lower HGB might be explained with both higher prev-
alence and severity of CKD among patients with lower 
decline in nocturnal SBP and higher prevalence of 
non-dipping pattern of hypertension among patients 
with CKD [29, 30]. In our study, there was higher 
prevalence of CKD among non-dippers and reverse-
dippers compared with dippers. With the worsening 
kidney function we observed lower HGB concentra-
tion [31]. Non-dipping patients are described to have 
impairment in autonomic nervous drive (especially 
parasympathetic inactivity) [32]. No studies regarding 
either HRmax or CK-MB and CBPP were found.
As both, the strength and the limitation of the 
study we see a relatively big subgroup of reverse-
dipper patients in our study population. It may be 
considered strength, since data regarding reverse-dip-
pers are mostly lacking, and this group of patients is 
frequently omitted in other studies. Though, it may 
be seen also as limitation, because we had no data 
to compare our outcomes. Further limitation of our 
study could be the fact that we divided patients based 
only on one ABPM outcome. We also included rela-
tively small group of patients in the study.
Conclusions
We found that detailed medical history could help 
us to predict not only nocturnal fall in SBP, but also 
patient’s CBPP. These findings may have influence 
arterial hypertension 2019, vol. 23, no. 3
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on care of patients with hypertension, though further 
studies are needed.
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